)
10X Genomics (TXG) investor relations material
10X Genomics Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Q4 2025 revenue reached $166 million, up 1% year-over-year and exceeding guidance; full-year revenue was $599 million excluding $44 million from patent litigation settlements, or $642.8 million including them.
Operating environment remained challenging with subdued customer spending and constrained capital equipment purchases, but underlying demand for solutions remained solid.
Single-cell consumables volumes grew at a double-digit rate each quarter, driven by adoption of lower-cost products like Flex and on-chip multiplexing.
Strategic partnerships and collaborations were established with Cancer Research Institute, PharosAI, Dana-Farber Cancer Institute, Brigham & Women's Hospital, and others to advance AI-driven and translational research.
Cash balance increased by over $130 million year-over-year, ending 2025 at $523.4 million.
Financial highlights
Q4 revenue grew 1% year-over-year, surpassing the high end of guidance.
Total consumables revenue for 2025 was $507.2 million, up from $493.4 million in 2024; instrument revenue declined to $56.8 million from $92.7 million.
Q4 gross margin was 68%, up from 67% the prior year; full-year gross margin was 69%.
Q4 operating expenses decreased 18% year-over-year to $132.6 million, mainly due to lower legal and personnel costs and a $49.9 million litigation settlement gain.
Q4 operating loss was $19.5 million, a significant improvement from $49.8 million in Q4 2024; full-year operating loss narrowed to $61.0 million from $194.6 million in 2024.
Outlook and guidance
2026 revenue expected between $600 million and $625 million, representing 0%-4% growth over 2025, excluding non-recurring 2025 license and royalty revenue.
Double-digit growth anticipated for single-cell consumables reactions and spatial consumables revenue.
CapEx funding expected to remain constrained, continuing to pressure instrument revenue.
Q1 2026 revenue projected to be a higher percentage of full-year revenue due to late Q4 orders shipped in January.
Continued focus on cost discipline and operating efficiency expected to further strengthen financial profile in 2026.
Next 10X Genomics earnings date
Next 10X Genomics earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage